US 12,064,409 B2
Action of L-citrulline to prevent or treat endothelial dysfunction
Gurdyal Kalsi, Potomac, MD (US); Frederick Barr, Little Rock, AR (US); Gary Pasternack, Baltimore, MD (US); and Marshall Summar, Washington, DC (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US); and ASKLEPION PHARMACEUTICALS, LLC, Baltimore, MD (US)
Filed by Asklepion Pharmaceuticals, LLC, Baltimore, MD (US); and Vanderbilt University, Nashville, TN (US)
Filed on Jun. 30, 2021, as Appl. No. 17/364,280.
Claims priority of provisional application 63/213,600, filed on Jun. 22, 2021.
Prior Publication US 2022/0401396 A1, Dec. 22, 2022
Int. Cl. A61K 31/198 (2006.01); A61P 11/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/198 (2013.01) [A61P 11/00 (2018.01); A61P 31/14 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating endothelial dysfunction in a patient, the method comprising administering an effective amount of citrulline to the patient, wherein the effective amount of citrulline is an amount sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) and/or an amount sufficient to reduce the formation of free radicals;
wherein the patient experiencing endothelial dysfunction has plasma levels of D-dimer above 250 ng/mL; and/or
wherein the effective amount of citrulline is sufficient to reduce plasma level of angiopoietin-2 by a detectable amount.